News Releases
Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
11/06/14Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 6, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeu... 
Printer Friendly Version
11/06/14Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 6, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress. Third Quarter Highlights and Progress: Due to a slower rate of enrollment than projected over the last quarter for Heron’s ongoing Phase 3 study of SUSTOL® (granisetron injection, ext... 
Printer Friendly Version
08/25/14Heron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and Secretary
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 25, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esmé C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron’s Chief Executive Officer. “Esme brings to her role at Heron over fifteen years of relevant legal and industry experience that will... 
Printer Friendly Version
08/04/14Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 4, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress. Recent Corporate Highlights On June 30, 2014, Heron announced the closing of an underwritten public offering of 4.8 million shares of common stock at a public offering price of ... 
Printer Friendly Version
06/30/14Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 30, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an a... 
Printer Friendly Version
06/25/14Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 25, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the pricing of an underwritten offering of 4,500,000 shares of its common stock, offered at a price of $11.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. As a component of the offering, in lieu of co... 
Printer Friendly Version
06/24/14Heron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 24, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration. All of the shares in the proposed offering are to be sold by Heron Therapeutics, Inc. Jefferies LLC and Leerink Partners LLC are acting as joint book-runners for t... 
Printer Friendly Version
06/20/14Heron Therapeutics Set to Join Russell 3000 Index
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 20, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that it is set to join the broad-market Russell 3000 Index, as well as the Russell Global and Russell Micro-Cap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.ru... 
Printer Friendly Version
06/12/14Heron Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 12, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 3:00 p.m. ET in New York City. A live webcast of this presentation will be available on the Company’s website at www.h... 
Printer Friendly Version
06/02/14Heron Therapeutics Provides Update on SUSTOL™ Program
- SUSTOL™ Phase 3 study in delayed-HEC patients progressing rapidly – over 100 site locations opened in first two months - Based on faster than expected start-up, Heron now plans to include delayed-HEC results in NDA resubmission planned for fourth quarter REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 2, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that it has achieved a rapid start-up of i... 
Printer Friendly Version
05/20/14Heron Therapeutics to Present at the Jefferies 2014 Global Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 20, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies 2014 Global Health Care Conference on Monday, June 2, 2014 at 3:00 p.m. ET in New York City. A live webcast of this presentation will be available on the Company’s website at www.herontx.com ... 
Printer Friendly Version
05/19/14Heron Therapeutics Announces Data on SUSTOL™ Program to be Presented at 2014 ASCO Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 19, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that data from a completed Phase 3 clinical trial of SUSTOL™ (granisetron), the Company’s lead product candidate for the prevention of acute-onset chemotherapy-induced nausea and vomiting (CINV), will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, June 1, 2014 in... 
Printer Friendly Version
05/14/14Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program
Advanced Biochronomer™ combination product formulation HTX-011 demonstrates significantly reduced pain compared to Exparel® for up to 72 hours post-surgery REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 14, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced that it has selected HTX-011, a unique combination product utilizing its proprietary Biochronomer™ polymer-based drug delivery platf... 
Printer Friendly Version
05/08/14Heron Therapeutics Announces First Quarter 2014 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 8, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today reported first quarter 2014 financial results and highlighted recent corporate progress and upcoming milestones. “During the first quarter, we achieved a major milestone with the initiation of a Phase 3 label expansion study of SUSTOL™ (granisetron), our lead product candidate for the prevention of CINV,” commente... 
Printer Friendly Version
05/01/14Heron Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 1, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry Quart, Pharm.D., Chief Executive Officer of Heron, will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 11:20 a.m. PT in Las Vegas, NV. A live webcast of this presentation will be available on the Company’s website at www.herontx.c... 
Printer Friendly Version
03/31/14Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL™
Study will evaluate the prevention of delayed-onset chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 31, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company’s lead product candidate for the prevention of chemotherapy-induced nausea an... 
Printer Friendly Version
03/05/14Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (HRTX), a specialty pharmaceutical company, today reported fourth quarter and full year 2013 financial results and highlighted recent corporate progress. “In the last 12 months, we transformed ourselves into Heron Therapeutics and made important advancements to position Heron for success in 2014,” said Barry D. Quart, PharmD, Chief Executive Officer of Heron Therapeutics. “In 2013, we brought in a fresh and highly seasoned manage... 
Printer Friendly Version
01/27/14Heron Therapeutics Provides Update on Sustol Resubmission
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company's timeline for the resubmission of the new drug application (NDA) for Sustol® to the U.S. Food and Drug Administration (FDA), the Company's product candidate for chemotherapy-induced nausea and vomiting (CINV). "Subject to the FDA's review and approval of the Sustol NDA, we project being in a position to launch Sust... 
Printer Friendly Version
01/23/14Heron Therapeutics Announces Relisting on NASDAQ
January 23, 2014 08:00 AM Eastern Standard Time REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc., OTCBB: APPAD), a specialty pharmaceutical company, today announced that the Company’s common stock has been relisted on the NASDAQ Capital Market. The Company’s shares will trade under the symbol “HRTX” on the NASDAQ Capital Market when the market opens today, Thursday, January 23, 2014. “We ... 
Printer Friendly Version
01/13/14A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, today announced that it has changed its name to Heron Therapeutics, Inc. and effected a 1-for-20 reverse stock split, both effective January 13, 2014. The reverse split is being implemented to increase the Company's stock price in support of the Company's pending application to list on the NASDAQ Capital Market. Assuming satisfaction of listing standards, the Company expects to list on NAS... 
Printer Friendly Version
11/25/13A.P. Pharma Closes Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 25, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 150,000,000 shares of common stock at a public offering price of $0.40 per share. Gross proceeds to A.P. Pharma are $60,000,000, before deducting underwriting discounts and commissions and offering expenses payable by A.P. Pharma. Jefferies LLC a... 
Printer Friendly Version
11/20/13A.P. Pharma Announces Pricing of Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 20, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the pricing of an underwritten offering of 150,000,000 shares of its common stock, offered at a price of $0.40 per share. The offering is expected to close on or about November 25, 2013, subject to customary closing conditions. In addition, A.P. Pharma has granted the underwriters a 30-day option to purchas... 
Printer Friendly Version
11/19/13A.P. Pharma Announces Proposed Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 19, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced its intention to offer and sell shares of its common stock to “Qualified Institutional Buyers” in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by A.P. Pharma. Jefferies LLC and Leerink Swann LLC are acting as joint book-runners for the offering. JMP Securities L... 
Printer Friendly Version
11/12/13A.P. Pharma Announces Pipeline Expansion
‒ First program moving into development is a long-acting anesthetic for post-surgical pain ‒ ‒ Planned post marketing study for Sustol with goal of label expansion in delayed onset CINV in patients receiving HEC regimens ‒ REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported it has initiated a program to expand its pipeline of sustained rele... 
Printer Friendly Version
11/12/13A.P. Pharma Announces Third Quarter 2013 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended September 30, 2013. “During the third quarter, we made significant progress toward resubmission of the NDA for Sustol™ (formerly known as APF530) targeted for the end of the first quarter 2014,” said Dr. Barry Quart, CEO of A.P. Pharma. “Today, we also s... 
Printer Friendly Version
11/04/13A.P. Pharma Makes Key Management Appointments
– Paul Marshall Appointed Senior Vice President, Technical Operations – – Brian Drazba, CPA Appointed Vice President, Finance and Chief Financial Officer – REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 4, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Paul Marshall as senior vice president of technical operations and Brian Drazba as vice president of finance and chief financial officer. Mr. Marshall will be responsible for A.P.... 
Printer Friendly Version
08/08/13A.P. Pharma, Inc. Announces Planned Name Change to “Heron Therapeutics, Inc.” and Application to List on NASDAQ Capital Market
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, announced today that it has filed an application to list the Company’s common stock on the NASDAQ Capital Market. In addition, the Company’s Board of Directors has, subject to stockholder approval, approved proposals to rename the Company "Heron Therapeutics, Inc." and to implement a reverse split of its common stock. The reverse ... 
Printer Friendly Version
08/08/13A.P. Pharma Announces Second Quarter 2013 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended June 30, 2013. “Over the past couple of months, the new management team and Board of Directors have focused on advancing the Company and its lead program,” said Barry Quart, PharmD., A.P. Pharma’s Chief Executive Officer. “These activities included our evaluatio... 
Printer Friendly Version
07/08/13A.P. Pharma to Present at 8th Annual JMP Securities Healthcare Conference
A.P. Pharma to Present at 8th Annual JMP Securities Healthcare Conference REDWOOD CITY, Calif.—July 8, 2013 -- (BUSINESS WIRE)-- A.P. Pharma, Inc. (OTCBB:APPA.OB), a specialty pharmaceutical company, announced that Barry Quart, Pharm D., the Company's Chief Executive Officer, will be presenting at the Eighth Annual JMP Securities Healthcare Conference on Tuesday, July 9, 2013 in New York City. The following are specific details regarding A.P. Pharma’s presentation at the conference: Ev... 
Printer Friendly Version
05/10/13A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 10, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for first quarter ended March 31, 2013 and highlighted recent corporate progress. Financial Results and Operational Highlights On May 2, 2013, the Company announced that the A.P. Pharma Board of Directors had appointed a new management team to lead the Company. This team includes Barry D. Quart, Pharm.D., who joined the Company as Chi... 
Printer Friendly Version
05/02/13A.P. Pharma Appoints New Management Team
- Barry D. Quart, Pharm.D. Appointed Chief Executive Officer - - Robert Rosen Appointed President - - Steve Davis Appointed Chief Operating Officer - REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 2, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that its Board of Directors has appointed a new management team to lead the Company. Effective today, Barry D. Quart, Pharm.D. will join the Company as Chief Executive Officer, Robert Rosen, who joined ... 
Printer Friendly Version
03/28/13A.P. Pharma Receives FDA Complete Response Letter for APF530
- Company Revises Projected Launch Timing from 2H 2013 to 1H 2014 - - Conference Call to Be Held at 8:30 a.m. Eastern Time - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 28, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its lead product candi... 
Printer Friendly Version
03/01/13A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2013-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported fourth quarter and full year 2012 financial results and highlighted recent corporate progress. “We achieved several critical objectives in 2012, highlighted by the resubmission of our New Drug Application for APF530 to FDA in September. Additionally, we have made a number of key appointments to th... 
Printer Friendly Version
02/28/13A.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 28, 2013-- A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Jesse Hollingsworth as vice president of sales. “Jesse brings over a decade of highly relevant oncology sales experience, including a significant amount of knowledge working with group purchasing organizations,” said Robert Rosen, A.P. Pharma’s chief commercial officer. “Over the past several months, A.P. Pharma has been focused on recruiting key additions to our management... 
Printer Friendly Version
12/17/12A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530
– Joel Schaedler named as Vice President of Market Access – – Daniel Martin named Vice President of Marketing – REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 17, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Joel Schaedler as vice president of market access and Daniel Martin as vice president of marketing. Mr. Schaedler will be responsible for the Company’s market access programs for APF530, the Company’s lead product candidat... 
Printer Friendly Version
12/13/12A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 13, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Mark S. Gelder, M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if app... 
Printer Friendly Version
11/05/12A.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended September 30, 2012 and highlighted recent corporate progress. "A.P. Pharma's accomplishments over the quarter have put us in a strong position as we approach a new era for the organization and begin preparing for commercialization of APF530," said John B. Whelan, A.P. Pharma's president and chief executive officer. ... 
Printer Friendly Version
10/18/12A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 18, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen as senior vice president and chief commercial officer. Mr. Rosen will oversee all of A.P. Pharma’s commercial activities, including the commercial launch of APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. Mr. Rosen also will continue to serve as a dir... 
Printer Friendly Version
10/16/12A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 16, 2012-- A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of its New Drug Application (NDA) for APF530. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013. APF530 is a long-acting formulation of granisetron and is being developed for the pr... 
Printer Friendly Version
09/28/12A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 28, 2012-- A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma expects confirmation of acceptance from the FDA and a Prescription Drug User Fee Act (PDUFA) goal date within ... 
Printer Friendly Version
09/10/12A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2012-- A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Thomas Pitler, Ph.D. as vice president of business development. "Tom has extensive business development experience in establishing long-term collaborations around platform technologies," said John B. Whelan, A.P. Pharma's president and chief executive officer. "As we look toward the potential commercialization of APF530, we are focusing on opportunities that support not jus... 
Printer Friendly Version
08/02/12A.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 2, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today reported financial results for the quarter ended June 30, 2012 and highlighted recent corporate progress. "With the recent closing of our common stock offering, we are in a strong financial position as we approach the commercialization phase with our lead product candidate, APF530, for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and... 
Printer Friendly Version
07/31/12A.P. Pharma Appoints Robert Rosen to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 31, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen to its board of directors. "We are delighted that Robert has chosen to join the A.P. Pharma board," stated Kevin C. Tang, A.P. Pharma's chairman of the board. "Robert's particular expertise in commercializing oncology drugs will be instrumental as we enter the commercialization phase with our lead product, APF530, for the... 
Printer Friendly Version
07/25/12A.P. Pharma to Raise $53.6 Million in Common Stock Offering
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 25, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing institutional investors relating to a private placement of common stock. In the transaction, the investors have agreed to purchase 102,000,000 shares at $0.525 per share, resulting in gross proceeds of approximately $53.6 million. The transaction is expected to close on or around... 
Printer Friendly Version
07/10/12A.P. Pharma Announces the Allowance of Three Patents Covering APF530
– APF530 patent protection extended through 2024 – REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 10, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has allowed three new patents covering the Company’s lead product candidate, APF530, which is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The newly allowed patents, when is... 
Printer Friendly Version
06/29/12A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
- Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology International Symposium - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 29, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV). The findings from the analysis of this subset of data indicate that APF530 offere... 
Printer Friendly Version
06/21/12A.P. Pharma Appoints Barry Quart and Stephen Davis to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 21, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Barry D. Quart, Pharm.D., and Stephen R. Davis, to its board of directors. Both Dr. Quart and Mr. Davis are members of the executive management team of Ardea Biosciences, which recently was acquired by AstraZeneca (NYSE: AZN) for $1.26 billion. Their appointments bring the number of A.P. Pharma board members to six. "Barry and Steve b... 
Printer Friendly Version
06/20/12A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
- Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology International Symposium - REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 20, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that the Company will present patient-satisfaction data from its Phase 3 trial of APF530 at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) ... 
Printer Friendly Version
05/31/12A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control
- Phase 3 Data Abstract Accepted by American Society of Clinical Oncology for Publication at Annual Meeting - REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 31, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting. APF530 is the Company's lead product candidat... 
Printer Friendly Version
05/10/12A.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 10, 2012-- A.P. Pharma, Inc. (OTCBB:APPA.OB), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2012 and highlighted recent corporate progress. "In the first quarter of 2012, we completed several key studies to support the resubmission of our New Drug Application for APF530, which is expected to occur in mid-2012," said John B. Whelan, A.P. Pharma's president and chief executive officer. "If ap... 
Printer Friendly Version
03/26/12APF530 Thorough QT Study Showed No Effect on Cardiac Repolarization
Results to Be Included in APF530 New Drug Application Resubmission Targeted for Mid-2012 REDWOOD CITY, CA, Mar 26, 2012 (MARKETWIRE via COMTEX) --A.P. Pharma, Inc. (OTCBB: APPA) today announced results of its thorough QT (tQT) study of APF530, its lead product candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The study was conducted to assess the potential for granisetron, the active drug in APF530, to prolong the QT ... 
Printer Friendly Version
03/26/12A.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530
REDWOOD CITY, CA, Mar 26, 2012 (MARKETWIRE via COMTEX) --A.P. Pharma, Inc. (OTCBB: APPA) today reported fourth quarter and full year 2011 financial results and provided an update on its lead product candidate, APF530, being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). "In 2011 we made solid progress on the work necessary to respond to the APF530 Complete Response Letter and to prepare the resubmission of the New Drug Application... 
Printer Friendly Version
03/26/12A.P. Pharma Appoints Thomas Ottoboni, Ph.D. as Vice President of Pharmaceutical Development
REDWOOD CITY, CA, Mar 26, 2012 (MARKETWIRE via COMTEX) --A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Thomas Ottoboni, Ph.D. as Vice President of Pharmaceutical Development. "We are extremely pleased to have Tom join A.P. Pharma. His considerable expertise in drug development and drug delivery systems will make him a valuable addition to our management team," stated John B. Whelan, A.P. Pharma's president and chief executive officer. Dr. Ottoboni was most recently Vice ... 
Printer Friendly Version
01/06/12A.P. Pharma to Present at OneMedForum 2012 Financial Conference
REDWOOD CITY, CA--(Marketwire -01/06/12)- A.P. Pharma, Inc. (OTC.BB: APPA.OB) - News, a specialty pharmaceutical company, today announced that the Company will present at the OneMedForum San Francisco 2012 Finance Conference on January 11, 2012 at 10:45 a.m. PST. The conference will be held at the Sir Francis Drake Hotel in San Francisco. A.P. Pharma management will provide an overview of recent corporate progress. About A.P. Pharma A.P. Pharma is a specialty pharmaceutical company developing... 
Printer Friendly Version
11/07/11A.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate Progress
REDWOOD CITY, Calif., Nov 07, 2011 (BUSINESS WIRE) --A.P. Pharma, Inc. (OTCQB: APPA.PK), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2011 and highlighted its recent corporate progress. Operational Highlights On July 1, 2011, the Company closed a $24.0 million private placement of common stock and warrants. In July 2011, the Company commenced a thor... 
Printer Friendly Version
08/08/11A.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate Progress
REDWOOD CITY, Calif., Aug 08, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (OTCQB:APPA.PK), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress. Operational Highlights On May 2, 2011, A.P. Pharma closed a private placement financing for $1.5 million in convertible notes, with an additional $3.0 million available to the Company at the investors' discretion within two years of the closing ... 
Printer Friendly Version
06/29/11A.P. Pharma to Raise $24 Million in Private Placement of Common Stock and Warrants
Proceeds to Fund Resubmission Activities Relating to APF530 NDA REDWOOD CITY, Calif., Jun 29, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (OTCQB:APPA.PK), a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds. The common stock and warrants are being sold in units at a price o... 
Printer Friendly Version
05/16/11A.P. Pharma Announces First Quarter 2011 Financial Results and Recent Corporate Progress
REDWOOD CITY, Calif., May 16, 2011 (BUSINESS WIRE) --A.P. Pharma, Inc. (OTCQB:APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2011 and highlighted its recent corporate progress. "A.P. Pharma has made significant strides in 2011, including productive meetings with the Food and Drug Administration and a private placement financing of up to $4.5 million in gross proceeds to fund our contin... 
Printer Friendly Version
04/25/11A.P. Pharma Announces Financing of Up to $4.5 Million and Names CEO and COO
REDWOOD CITY, Calif., Apr 25, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (OTCQB: APPA), a specialty pharmaceutical company, today announced that it has entered into definitive agreements with investors, including Tang Capital Partners, LP, for a private placement of up to $4.5 million in convertible notes. The transaction is expected to close on or about April 29, 2011, subject to the satisfaction of certain closing conditions. Upon the closing, an initial amount of $1.5 million will be funded to... 
Printer Friendly Version
04/25/11A.P. Pharma Provides Regulatory Update on APF530 NDA
- NDA Resubmission Targeted for the First Half of 2012 - REDWOOD CITY, Calif., Apr 25, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (OTCQB: APPA), a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Company management and consultants met with the U.S. Food and Drug Administration (FDA) on March 31, 2011 to discuss certain aspects of the Complete Response Letter issued by the F... 
Printer Friendly Version
03/31/11A.P. Pharma Announces Transfer to OTCQB
REDWOOD CITY, Calif., Mar 31, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that beginning April 1, 2011 its common stock will be transferred from The NASDAQ Stock Market (NASDAQ) to the OTCQB, which is operated by OTC Markets, Inc. OTCQB is a market tier of OTC Markets for U.S. companies registered with and reporting to the Securities and Exchange Commission (SEC). The move from NASDAQ to OTCQB is due to A.P. Pharma's non-complia... 
Printer Friendly Version
03/28/11A.P. Pharma Announces Fourth Quarter and Full Year 2010 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Mar 28, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2010 and provided a corporate update. "Since receiving the Complete Response Letter on our APF530 New Drug Application, A.P. Pharma's management and staff have been working to address the issues raised by the Food and Drug Administration (FDA) and to prepare for meetings with the FDA,"... 
Printer Friendly Version
02/09/11A.P. Pharma Provides Update on APF530 Program and NASDAQ Listing
REDWOOD CITY, Calif., Feb 09, 2011 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration (FDA) in March 2010. The Company also announced that it has met with the NASDAQ Listing and Qualifications Panel (Panel) and is now awaiting its decision regarding A.P. Pharma's eligibility for continued l... 
Printer Friendly Version
11/22/10A.P. Pharma Receives Second Letter from NASDAQ Regarding Notice of Non-Compliance; Company to Request Hearing
REDWOOD CITY, Calif., Nov 22, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that, on November 17, 2010, it received a second letter from the Listing Qualifications Staff of The NASDAQ Stock Market (NASDAQ) indicating that it has not regained compliance with Listing Rule 5550(a)(2), which requires the closing bid price of the Company's common stock to be $1.00 or more. This letter is a follow-up to the letter received from NASD... 
Printer Friendly Version
11/15/10A.P. Pharma Announces Third Quarter 2010 Financial Results
REDWOOD CITY, Calif., Nov 15, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2010. Operational Highlights "A. P. Pharma has been working diligently to address the issues raised in the U.S. Food and Drug Administration's Complete Response Letter of March 2010," said John Whelan, A.P. Pharma's acting chief executive officer. "Our goal is to schedule what we hope will be a pr... 
Printer Friendly Version
08/16/10A.P. Pharma Announces Second Quarter 2010 Financial Results
REDWOOD CITY, Calif., Aug 16, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010. Operational Highlights In May, the Company engaged a leading regulatory consulting group to lead the U.S. Food and Drug Administration (FDA) review process and assist in preparing its resubmission of a New Drug Application (NDA) for APF530. The Company continues to work diligently toward the... 
Printer Friendly Version
05/26/10A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process
REDWOOD CITY, Calif., May 26, 2010 (BUSINESS WIRE) --A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has hired a leading consulting practice in pharmaceutical regulatory affairs to lead the U.S. Food and Drug Administration (FDA) review process and formed a special committee of the Board to oversee the Company's regulatory affairs. These actions have been taken to maximize the probability of approval by the FDA of APF530, its lead product candidate fo... 
Printer Friendly Version
05/20/10A.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
REDWOOD CITY, Calif., May 20, 2010 (BUSINESS WIRE) --A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2). The Company has been provided 180 calendar days, or until Novembe... 
Printer Friendly Version
05/17/10A.P. Pharma Announces First Quarter 2010 Financial Results
REDWOOD CITY, Calif., May 17, 2010 (BUSINESS WIRE) --A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2010. "Our focus is on addressing the issues raised in the Complete Response Letter we received for APF530 in March 2010," stated Ronald Prentki, A.P. Pharma's president and chief executive officer. "We are working with the U.S. Food and Drug Administration to schedule an End of Review meeting and have ... 
Printer Friendly Version
03/19/10A.P. Pharma Receives FDA Complete Response Letter for APF530
- Company to host conference call at 9:00 a.m. ET on Friday, March 19, 2010 -REDWOOD CITY, Calif., Mar 19, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formul... 
Printer Friendly Version
03/15/10A.P. Pharma Announces Fourth Quarter and Year-End 2009 Financial Results
REDWOOD CITY, Calif., Mar 15, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009. "2009 was an important year for A.P. Pharma. We achieved a major milestone with the submission of a New Drug Application for APF530, which is being developed for the prevention of chemotherapy-induced nausea and vomiting," said Ronald Prentki, A.P. Pharma's president and chief e... 
Printer Friendly Version
02/19/10A.P. Pharma Appoints Stephen R. Davis to Its Board of Directors
REDWOOD CITY, Calif., Feb 19,  2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced the appointment of Stephen Davis to its board of directors. Mr. Davis was the chief executive officer for Neurogen Corporation, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of A.P. Pharma board members to seven. "Steve's industry experience and extensive business acumen will make him a valuable addition... 
Printer Friendly Version
01/11/10A.P. Pharma Receives $2.5 Million Milestone Payment
REDWOOD CITY, Calif., Jan 11, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare. The payment represents a milestone payment that recently became payable to the Company under the agreement that the Company entered into on October 1, 2005 to sell its royalty rights to Retin-A Micro(R) and Carac(R) to an affiliate of the Paul Royalty Fun... 
Printer Friendly Version
01/11/10A.P. Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
REDWOOD CITY, Calif., Jan 11, 2010 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1). Pursuant to Nasdaq's rules, the Company was required to achieve a closing bid price of at l... 
Printer Friendly Version
11/23/09A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 23, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on November 19, 2009, the Company received notice from the Nasdaq Listing Qualifications Panel that it has regained compliance with the shareholders’ equity requirement for continued listing on the Nasdaq Capital Market. As announced on September 21, 2009, the Company received notice from The ... 
Printer Friendly Version
11/16/09A.P. Pharma Reports Third Quarter 2009 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 16, 2009-- A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009. Results of Operations A.P. Pharma’s net loss for the third quarter 2009 was $1.2 million, or $0.04 per share, compared with a $6.2 million net loss, or $0.20 per share, for the third quarter of 2008. The decreased net loss fo... 
Printer Friendly Version
10/28/09A.P. Pharma to Transfer to Nasdaq Capital Market
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 28, 2009-- A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that on October 26, 2009, the Company received notice that the Nasdaq Listing Qualifications Panel (Panel) has granted the Company’s request to transfer the listing of the Company’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market, which will take effect with the opening of the market on Wednesda... 
Printer Friendly Version
10/20/09A.P. Pharma Announces Private Equity Placement
Company to Raise $8.1 Million to Fund NDA Stage Program REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 20, 2009-- A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced it has entered into a definitive securities purchase agreement with certain existing accredited investors providing for a private placement of up to $13.1 million in two tranches, the first consisting of common stock and warrants with aggregate proceeds of... 
Printer Friendly Version
09/21/09A.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on September 15, 2009, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5450(a)(1). The Company ... 
Printer Friendly Version
09/15/09A.P. Pharma and Merial Enter into Worldwide Agreement
– Merial to develop pain management product using A.P. Pharma’s Biochronomer™ polymer technology – REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 15, 2009-- A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product . The product, which contains an undisclosed analge... 
Printer Friendly Version
08/04/09A.P. Pharma Reports Second Quarter 2009 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 4, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2009. Results of Operations A.P. Pharma’s net loss for the second quarter was $3.9 million, or $0.13 per share, compared with a $6.1 million net loss, or $0.20 per share, for the second quarter of 2008. The decreased net loss for the sec... 
Printer Friendly Version
07/20/09A.P. Pharma Receives Nasdaq Notice of Non-Compliance; Company to Request Hearing
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 20, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on July 17, it received notice from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that it has not regained compliance with Nasdaq Marketplace Rule 5450(b)(1)(A), the minimum stockholders’ equity requirement. As a result, the Company’s securities would be subject to delistin... 
Printer Friendly Version
07/20/09A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 20, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for APF530 for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron that utilizes the Company’s proprietary Biochronomer™ drug delivery ... 
Printer Friendly Version
06/03/09A.P. Pharma Receives Extension for Nasdaq Listing Compliance
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 3, 2009-- A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that on May 29, 2009, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq) granting A.P. Pharma an extension to regain compliance with the minimum $10 million stockholders' equity requirement for continued listing on The Nasdaq Global Market under Nasdaq Marketplace ... 
Printer Friendly Version
06/01/09A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology
REDWOOD CITY, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Jun. 1, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced additional findings from the Company’s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV). The new data were included in a poster presentation during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). APF530 is a long-acting formu... 
Printer Friendly Version
05/29/09A.P. Pharma Announces Additional Restructuring Effort
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 29, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has implemented a reduction of its staff representing approximately 34% of its work force. The actions are being taken to allow the Company to provide the resources needed to continue advancing its lead program, APF530, towards regulatory approval and commercialization. APF530 is a long-acting formulation... 
Printer Friendly Version
05/18/09A.P. Pharma Submits New Drug Application for APF530 in Chemotherapy-Induced Nausea and Vomiting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 18, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) for its lead product, APF530, to the U.S. Food and Drug Administration (FDA). APF530 is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is a long-acting formulation of granisetron that utilizes the Company’s proprietary ... 
Printer Friendly Version
05/18/09APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 18, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that data from the Company’s pivotal phase 3 trial of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held from May 29 to June 2, 2009 in Orlando, Florida. APF530 is a long-... 
Printer Friendly Version
05/14/09A.P. Pharma Reports First Quarter 2009 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May. 14, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2009. Operational Highlights A.P. Pharma continued to make significant progress towards filing a New Drug Application (NDA) for its lead program, APF530. The Company expects to file the NDA with the U.S. Food and Drug Administration (FD... 
Printer Friendly Version
04/07/09A.P. Pharma Receives Nasdaq Stockholder Equity Notification
REDWOOD CITY, Calif., Apr 07, 2009 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that, on April 2, 2009, the Company received notification from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") that it is not in compliance with the minimum $10 million stockholders' equity requirement for continued listing on the Nasdaq Global Market under Nasdaq Marketplace Rule 4450(a)(3)... 
Printer Friendly Version
03/31/09A.P. Pharma Announces Fourth Quarter and Year-End 2008 Financial Results and Provides Update on APF530 NDA
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 31, 2009-- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2008. In addition, the Company provided an update on the status of its new drug application (NDA) for APF530. APF530, the Company's proprietary, sustained-release formulation of granisetron, is being developed for the prevention of chemother... 
Printer Friendly Version
02/25/09A.P. Pharma Appoints John B. Whelan as Chief Financial Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 25, 2009-- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that John B. Whelan has been appointed to the role of vice president, finance and chief financial officer effective February 23, 2009. Mr. Whelan replaces Gregory Turnbull, who was serving as interim chief financial officer and will remain a company director and a member of the board's executive committee. ... 
Printer Friendly Version
12/18/08A.P. Pharma Revises Target Date for APF530 NDA
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 18, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today provided an update on the timing for the submission of the New Drug Application (NDA) for APF530, the company's lead product, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV). Together with its regulatory consultants, the company recently completed a comprehensive review ... 
Printer Friendly Version
11/05/08A.P. Pharma Reports Results for the Third Quarter 2008
Company Presents New Phase 3 Clinical Data for APF530 and Announces Cost Reduction Actions REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2008--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2008. The company also announced additional positive clinical data for its lead product, APF530, which has successfully completed a Phase 3 trial for the treatment of chemotherapy-i... 
Printer Friendly Version
11/03/08A.P. Pharma to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 3, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that Ronald J. Prentki, the Company's president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, on Wednesday, November 12, 2008, at 10:20 a.m. Eastern time at The Palace Hotel in New York City. Interested parties can access a live audio webcast at www.appharma.com. An archived presentation wi... 
Printer Friendly Version
10/29/08A.P. Pharma to Hold 2008 Third Quarter Financial Results Conference Call November 5
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 29, 2008--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will release its 2008 third quarter financial results before the market opens on Wednesday, November 5, 2008. The Company's Chief Executive Officer Ronald Prentki will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday, November 5, 2008 to discuss the financial results, provide a business up... 
Printer Friendly Version
09/30/08A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV
Company on Track to Submit NDA in the Fourth Quarter of 2008 Conference Call Begins Today at 9:00 A.M. Eastern Time REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive results from its pivotal Phase 3 study comparing the efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi(R) for the prevention of chemotherapy induced nausea and vomiting (CINV). Patients... 
Printer Friendly Version
09/29/08A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will announce clinical trial results from its pivotal Phase 3 trial for APF530 for the prevention of chemotherapy induced nausea and vomiting (CINV) before the market opens on Tuesday, September 30, 2008. The Company will hold an investment-community conference call beginning at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) on Tuesday, September 30, 2008 to discuss the ... 
Printer Friendly Version
08/14/08A.P. Pharma Reports Results for the Second Quarter 2008
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 14, 2008--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2008. Highlights Operational: -- Ronald Prentki appointed President, Chief Executive Officer and Director -- APF530 (prevention of chemotherapy-induced nausea and vomiting) -- Patient enrollment completed in Phase 3 trial -- Announcement of trial results ... 
Printer Friendly Version
07/31/08A.P. Pharma to Hold 2008 Second Quarter Financial Results Conference Call August 14
REDWOOD CITY, Calif., Jul 31, 2008 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2008 second quarter financial results before the market opens on Thursday, August 14, 2008. The Company's Chief Executive Officer Ronald Prentki will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, August 14, 2008 to discuss the financial results, provide a business update and answ... 
Printer Friendly Version
07/09/08A.P. Pharma Announces Stock Option Grant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 9, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, announced today it has made a stock option grant to Ronald J. Prentki, who joined the company on July 7, 2008 as President and Chief Executive Officer, for 1,400,000 shares. The options have a ten year life, vest on a four year schedule, and have an exercise price of $1.19 per share, the closing price of the company's common stock on the date of the grant. Th... 
Printer Friendly Version
07/07/08A.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 7, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, has appointed Ronald J. Prentki as President, Chief Executive Officer and a member of the company's board of directors, effective July 7, 2008. Mr. Prentki succeeds Gregory Turnbull, who will remain a company director, a member of the board's executive committee and, until a permanent successor is recruited, interim chief financial officer. "I am delighted to w... 
Printer Friendly Version
06/23/08A.P. Pharma Completes Enrollment in Phase 3 Trial of APF530
REDWOOD CITY, Calif., Jun 23, 2008 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, has completed patient enrollment in its pivotal Phase 3 study in chemotherapy-induced nausea and vomiting (CINV) comparing the efficacy of APF530 (a proprietary, sustained release formulation of granisetron) with Aloxi for the prevention of acute and delayed onset CINV in both moderate and highly emetogenic chemotherapy treatments. The trial is being conducted in the U... 
Printer Friendly Version
05/15/08A.P. Pharma Reports Results for the First Quarter 2008
APF530 Phase 3 Trial Close to Completion REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 15, 2008--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2008. Highlights Operational: -- APF530 (Prevention of CINV) -- Patient enrollment almost complete -- Announcement of trial results targeted for Q3 2008 -- NDA submission planned for late 2008 -- APF112 (Post-surgical... 
Printer Friendly Version
05/12/08A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 12, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2008 first quarter financial results before the market opens on Thursday, May 15, 2008. Company executives will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, May 15, 2008 to discuss the financial results, provide a business update and answer questions. To participate... 
Printer Friendly Version
03/31/08A.P. Pharma Announces Stock Option Grants
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 31, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, announced today it has made option grants to two newly-hired non-executive employees for a total of 50,000 shares. The options have a ten year life, vest on a four year schedule, and have an exercise price of $1.30, the closing price of the Company's common stock on the date of the grant. The options were granted under A.P. Pharma's 2000 Non-Qualified Stock... 
Printer Friendly Version
03/13/08A.P. Pharma Reports Results for the Fourth Quarter and Full Year 2007
APF530 Phase 3 Trial Enrollment Nears CompletionREDWOOD CITY, Calif., Mar 13, 2008 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2007. Highlights Operational: -- APF530 (Prevention of chemotherapy-induced nausea and vomiting, or CINV) -- Patient enrollment nearing completion -- Announcement of trial results targeted for Q3 2008 -- NDA ... 
Printer Friendly Version
03/10/08A.P. Pharma to Hold 2007 Fourth Quarter Financial Results Conference Call March 13
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 10, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2007 fourth quarter financial results before the market opens on Thursday, March 13, 2008. Company executives will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, March 13, 2008 to discuss the financial results, provide a business update and answer questions. To part... 
Printer Friendly Version
01/16/08A.P. Pharma Announces Stock Option Grant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 16, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced it has made an option grant for 30,000 shares at an exercise price of $1.37 (the closing price as of the date of the grant) to a new employee, as an inducement to the individual entering into employment with the company, under the 2000 Non-Qualified Stock Option Plan. The options have a 10 year life and vest over a four year period. About A.P... 
Printer Friendly Version
01/14/08A.P. Pharma Announces Executive Officer Departure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 14, 2008--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, announced today that Michael O'Connell, its Chief Operating Officer and Chief Financial Officer, will be leaving the company on January 18, 2008. Mr. O'Connell originally joined A.P. Pharma in 1992 as Vice President and Chief Financial Officer. In 2000 he was named President and Chief Executive Officer, and served in that capacity until departing in October of 20... 
Printer Friendly Version
01/02/08Dutton Associates Announces Investment Opinion: A.P. Pharma Rated Strong Speculative Buy in Update Report by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Jan. 2, 2008--Dutton Associates updates its coverage of A.P. Pharma, Inc. (Nasdaq:APPA), reiterating its Strong Speculative Buy rating and establishing a 12-month price target of $3.00. The 10-page report by Dutton Associates senior analyst Stephen L. Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals. A.P. Pharma is a specialty pharmaceutical company ... 
Printer Friendly Version
12/21/07A.P. Pharma Announces Chief Executive Officer Succession Plan
REDWOOD CITY, Calif., Dec 21, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that its board of directors has initiated an executive succession program designed to recruit a well-qualified successor for Gregory Turnbull, the Company's current President and Chief Executive Officer. Mr. Turnbull, a long-time director of the Company, assumed the CEO position in October 2006 when Michael O'Connell, the incumbent at that time, depart... 
Printer Friendly Version
12/14/07A.P. Pharma Stockholders Approve 2007 Equity Incentive Plan and Amendment to 1997 Employee Stock Purchase Plan
Company Also Makes Option Grant Under 2000 Stock Option PlanREDWOOD CITY, Calif., Dec 14, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced the results of a special meeting of stockholders held December 14, 2007. Stockholders approved both items under consideration at the special meeting: 1) the adoption of the Company's 2007 Equity Incentive Plan comprising 3,000,000 shares of A.P. Pharma common stock reserved for issuance under t... 
Printer Friendly Version
11/13/07A.P. Pharma Reports Third Quarter Financial Results
Company Confirms Program Development Plans for 2008 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 13, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2007. Highlights Operational: -- APF530 (Prevention of CINV) -- Patient enrollment continues towards completion by Spring 2008 -- Trial results targeted for Q3 2008 -- NDA filing planned for late 2008 -- ... 
Printer Friendly Version
11/08/07A.P. Pharma to Hold 2007 Third Quarter Financial Results Conference Call November 13
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 8, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2007 third quarter financial results before the market opens on Tuesday, November 13, 2007. Paul Goddard, chairman, and Company management will host an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, November 13, 2007 to discuss the financial results, provide a business update and t... 
Printer Friendly Version
09/10/07A.P. Pharma to Present at Merriman Curhan Ford's Annual Investor Summit on September 17
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sept. 10, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that John Barr, Ph.D., the Company's vice president of Research and Development, will present at the Merriman Curhan Ford 4th Annual Investor Summit on Monday, September 17, 2007, at 11:15 a.m. Pacific time. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco. More information about the conference can be f... 
Printer Friendly Version
08/01/07A.P. Pharma Reports Second Quarter Financial Results
REDWOOD CITY, Calif., Aug 01, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2007. Highlights Financial: -- $40 million equity financing ($37.5 million net of expenses) successfully completed -- Sufficient capital to complete APF530 clinical trial and initiate new clinical programs -- New shareholders include premier healthcare investors -- ... 
Printer Friendly Version
07/25/07A.P. Pharma to Hold 2007 Second Quarter Financial Results Conference Call August 1
REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 25, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2007 second quarter financial results before the market opens on Wednesday, August 1, 2007. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday, August 1, 2007 to discuss the financial results, provide a business update... 
Printer Friendly Version
06/25/07A.P. Pharma Regains Compliance with NASDAQ Global Market Listing Requirements
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that based on the recent completion of a public offering of 24,393,939 shares of its common stock at a public offering price of $1.65 per share, the Company believes it has regained compliance for continued listing on the NASDAQ Global Market by satisfying the NASDAQ's minimum stockholders' equity requirement of the NASDAQ Marketplace Rule 4450(a)... 
Printer Friendly Version
06/19/07A.P. Pharma Closes $40 Million Common Stock Offering; Underwriters Exercise Full over-Allotment Option
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 19, 2007--A.P. Pharma, Inc. (NASDAQ:APPA, temporarily traded under the symbol "APPAD" until June 25, 2007 to reflect the recent reverse stock split), a specialty pharmaceuticals company, today announced the completion of a public offering of 24,393,939 shares of its common stock at a public offering price of $1.65 per share, including 3,181,818 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters.... 
Printer Friendly Version
06/14/07A.P. Pharma Prices $35 Million Common Stock Offering
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 14, 2007--A.P. Pharma, Inc. (NASDAQ:APPA, temporarily traded under the symbol "APPAD" until June 25, 2007 to reflect the recent reverse stock split), a specialty pharmaceuticals company, today announced the pricing of its underwritten public offering of 21,212,121 shares of its common stock at a public offering price of $1.65 per share, before underwriting discounts and commissions. The offering is expected to close on June 19, 2007, subject... 
Printer Friendly Version
06/07/07A.P. Pharma Receives $2.5 Million Milestone Payment
REDWOOD CITY, Calif., Jun 07, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced it has received a payment of $2.5 million from an affiliate of the Paul Royalty Fund. The payment represents a milestone payment that recently became payable to the Company under the agreement that the Company entered into on October 1, 2005 to sell its royalty rights to Retin-A Micro(R) and Carac(R) to an affiliate of the Paul Royalty Fund. About A.P.... 
Printer Friendly Version
05/24/07A.P. Pharma Clarifies Effective Date of Reverse Stock Split
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 24, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that trading of its shares on the Nasdaq Global Market will reflect the 1-for-4 reverse stock split beginning tomorrow, May 25, 2007. Previously the company had reported that trading of the company's stock would reflect the reverse split beginning today. About A.P. Pharma We are a specialty pharmaceutical company focused on developing ... 
Printer Friendly Version
05/23/07A.P. Pharma Stockholders Approve Reverse Stock Split
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 23, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported that its stockholders approved a reverse stock split of the company's outstanding shares of common stock at a ratio within a range of 1:2 to 1:4 in a vote at the annual stockholder meeting held May 23, 2007. Following this approval, A.P. Pharma is implementing an immediate 1-for-4 reverse stock split, which will be effective upon the beginning of... 
Printer Friendly Version
05/15/07A.P. Pharma Reports Receipt of Notice From NASDAQ
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 15, 2007--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported that on May 9, 2007, the Company was advised by the NASDAQ Listing Qualifications Department that NASDAQ is reviewing the Company's eligibility for continued listing on The NASDAQ Global Market as the Company does not comply with the NASDAQ's minimum $10 million stockholders' equity requirement set forth in Marketplace Rule 4450(a)(3). To facilitate... 
Printer Friendly Version
05/08/07A.P. Pharma Reports Results for the First Quarter 2007
Updates Progress of APF530 ProgramREDWOOD CITY, Calif., May 08, 2007 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2007. Highlights -- APF530 Development: -- Patient enrollment rates remain steady and lead to an NDA filing in 2008 -- Held successful Clinical Investigators meeting -- Filed an S-1 registration statement to raise additional capital ... 
Printer Friendly Version
05/01/07A.P. Pharma to Hold 2007 First Quarter Financial Results Conference Call May 8
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 1, 2007--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will release its 2007 first quarter financial results before the market opens on Tuesday, May 8, 2007. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, May 8, 2007 to discuss the financial results, provide a business update and to answ... 
Printer Friendly Version
04/05/07A.P. Pharma Files Registration Statement for a Common Stock Offering
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 5, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed public offering of up to $28,750,000 of its common stock. All of the shares in the proposed offering are being sold by the Company. Proceeds from this offering are intended to be used for clinical development of APF530, the Co... 
Printer Friendly Version
04/05/07A.P. Pharma's 10-K Report Audit Includes 'Going-Concern' Qualification
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 5, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, noted today that its financial statements for the fiscal year ended December 31, 2006, included in the Company's Annual Report on Form 10-K ("Form 10-K") filed on March 30, 2007, contain a going concern modification to the audit opinion from its independent accounting firm, Odenberg, Ullakko, Muranishi, & Co., LLP. As previously disclosed and discussed in Note 1 ... 
Printer Friendly Version
03/07/07A.P. Pharma Reports Results for the Fourth Quarter and Full Year 2006; Reports on Progress of APF530 Program
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 7, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2006. Highlights -- APF530 Development: -- Patient enrollment rates steady and lead to an NDA filing in 2008 -- Most patients are electing to proceed with multiple cycles of treatment -- Extended timeline for filing NDA ... 
Printer Friendly Version
02/28/07A.P. Pharma to Hold 2006 Fourth Quarter Financial Results Conference Call March 7
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 28, 2007--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2006 fourth quarter and year end financial results before the market opens on Wednesday, March 7, 2007. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday, March 7, 2007 to discuss the financial results, provide a busi... 
Printer Friendly Version
01/10/07Dutton Associates Announces Investment Opinion: AP Pharma Strong Speculative Buy In Update By Dutton Associates
EL DORADO HILLS, Calif., Jan 10, 2007 (BUSINESS WIRE) -- Dutton Associates updates its coverage of AP Pharma (Nasdaq:APPA) with an upgrade of its rating to Strong Speculative Buy. The 10-page report by Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. We are maintaining our Strong Speculative Buy rating, although our previous one-year price target of $3.00 per share ... 
Printer Friendly Version
12/21/06A.P. Pharma Resets APF530 NDA Filing Expectations
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 21, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, reported today that it believes that it will not meet a previously announced target of a 2007 filing of its New Drug Application (NDA) for APF530, currently in a Phase 3 clinical trial. Approximately 80% of the planned 80 clinical sites for the trial are now active. However, the rate at which sites are being activated continues to be slower than expected, even fol... 
Printer Friendly Version
11/20/06A.P. Pharma Names New Vice President of Clinical Development
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 20, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that Anastassios D. Retzios, Ph.D. has joined the Company in the newly created position of Vice President of Clinical Development, reporting to Gregory Turnbull, the Company's Chief Executive Officer. Dr. Retzios has more than 18 years of experience in a wide range of clinical and regulatory matters, most recently as Director of Global Clinical Res... 
Printer Friendly Version
11/07/06A.P. Pharma Reports 2006 Third Quarter Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 7, 2006--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2006. Highlights: APF530 Development: -- Clinical sites continue to be actively recruited and initiated. -- Patients afflicted with various types of cancer being enrolled and treated. -- Some patients have now completed multi... 
Printer Friendly Version
10/31/06A.P. Pharma to Hold 2006 Third Quarter Financial Results Conference Call November 7
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 31, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2006 third quarter financial results before the market opens on Tuesday, November 7, 2006. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, November 7, 2006 to discuss the financial results, provide a business update ... 
Printer Friendly Version
10/02/06A.P. Pharma Licenses APF530 to RHEI Pharmaceuticals for Development in Greater China
REDWOOD CITY, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct. 2, 2006--A.P. Pharma, Inc. (NASDAQ:APPA) and RHEI Pharmaceuticals, Inc. today announced that A.P. Pharma has granted an exclusive license to RHEI Pharmaceuticals to develop and sell APF530 in Greater China, which for the purposes of this agreement includes China, Taiwan, Hong Kong and Macau. APF530 is currently in Phase 3 trials in the U.S. for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ... 
Printer Friendly Version
09/28/06A.P. Pharma Expects Data from APF530 Pivotal Trial in Second Half of 2007
REDWOOD CITY, Calif., Sep 28, 2006 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that it expects to have initial data from its Phase 3 clinical trial with APF530 in the second half of 2007, and plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration before the end of 2007. Previously, the Company expected to have initial data from the Phase 3 trial in the first quarter of 2007. The revised timing is due... 
Printer Friendly Version
09/12/06A.P. Pharma to Present at Merriman Curhan Ford ''Investor Summit 2006'' on September 18
REDWOOD CITY, Calif., Sep 12, 2006 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced it will present at the Merriman Curhan Ford "Investor Summit 2006" to be held September 18-20 at the Mark Hopkins Hotel in San Francisco. Dr. Paul Goddard, A.P. Pharma's chairman, is scheduled to speak on Monday, September 18, at 4:00 p.m. Pacific time (7:00 p.m. Eastern time) and will discuss the Company's strategic initiatives and provide a busines... 
Printer Friendly Version
08/14/06A.P. Pharma Names Arthur Taylor to Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 14, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that Arthur T. Taylor has joined the Company's board of directors. Mr. Taylor has over 20 years' financial executive experience in the medical device, pharmaceutical and technology industries, and is currently Chief Operating Officer and Chief Financial Officer for Kyphon Inc., a medical device company based in Sunnyvale, California. "We are v... 
Printer Friendly Version
08/08/06A.P. Pharma Reports 2006 Second Quarter Results; Phase 3 Clinical Trial for APF530 Underway
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2006--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2006. Clinical and Financial Highlights APF530 Development: -- Phase 3 clinical trial protocol approved by FDA and governing IRB. -- Clinical sites actively being recruited and initiated. -- Cancer patients being enrolled and treated; patie... 
Printer Friendly Version
07/28/06A.P. Pharma to Hold 2006 Second Quarter Financial Results Conference Call August 8
REDWOOD CITY, Calif., Jul 28, 2006 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2006 second quarter financial results prior to market open on Tuesday, August 8, 2006. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, August 8, 2006 to discuss the financial results, provide a business update and to answer... 
Printer Friendly Version
06/27/06Dutton Associates Announces Investment Opinion: A.P. Pharma Maintained At Strong Speculative Buy Rating By Dutton Associates
EL DORADO HILLS, Calif., Jun 27, 2006 (BUSINESS WIRE) -- Dutton Associates updates its coverage of A.P. Pharma (Nasdaq:APPA) maintaining a Strong Speculative Buy rating and a $3.00 price target. The 8-page report by Dutton senior analyst Stephen Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. A.P. Pharma is a small, specialty pharmaceutical company seeking to develop and commercialize products ... 
Printer Friendly Version
05/10/06A.P. Pharma Reports 2006 First Quarter Results; Phase 3 Clinical Trial for APF530 Initiated
REDWOOD CITY, Calif., May 10, 2006 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2006. Recent and Financial Highlights -- Royalty interests sold for up to $30 million; $25 million cash received at closing. -- APF530 Phase 3 clinical trial protocol finalized following FDA input. -- IRB approval received and initiation of sites begun. -- Enrollment ... 
Printer Friendly Version
04/27/06A.P. Pharma Initiates APF530 Phase 3 Clinical Trial; IRB Approval Received
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 27, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported that the protocol for the Phase 3 clinical trial for APF530 has been finalized in cooperation with U.S. Food & Drug Administration (FDA) officials. Additionally, the company has received approval for the Phase 3 protocol for APF530 from the governing IRB that is responsible for overseeing the study. IRB approval of the protocol is the final step be... 
Printer Friendly Version
03/15/06A.P. Pharma Reports 2005 Full Year and Fourth Quarter Results; APF530 Phase 3 Clinical Trial Planning at Advanced Stage, Patient Enrollment Expected to Begin in April
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 15, 2006--A.P. Pharma, Inc. (NASDAQ NM: APPA), a specialty pharmaceutical company, today reported financial results for the year and three months ended December 31, 2005. Recent and Financial Highlights -- APF530 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients undergoing moderately and highly emetogenic chemotherapy: -- Held end of Phase 2 meeting with U.S. Fo... 
Printer Friendly Version
03/09/06A.P. Pharma to Hold 2005 Fourth Quarter Financial Results Conference Call March 15
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 9, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2005 fourth quarter financial results prior to market open on Wednesday, March 15, 2006. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday, March 15, 2006 to discuss the financial results, provide a business update an... 
Printer Friendly Version
02/08/06Dutton Associates Announces Investment Opinion: A.P. Pharma Inc. Strong Speculative Buy Rating and $3.00 Price Target Reiterated in Update by Dutton Associates
EL DORADO HILLS, Calif., Feb 08, 2006 (BUSINESS WIRE) -- Dutton Associates updates coverage of A.P. Pharma Inc. (Nasdaq:APPA) reiterating a Strong Speculative Buy rating and a 12-month price target of $3.00. The 7-page report by Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and other leading financial portals. A.P. Pharma is a specialty pharmaceutical company seeking to develop and commercialize products uti... 
Printer Friendly Version
01/24/06A.P. Pharma Announces Submission of APF530 Pivotal Trial Protocol for FDA Review; Phase 3 Trial to Compare APF530 With Palonosetron
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 24, 2006--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today announced it has submitted a protocol to the U.S. Food and Drug Administration (FDA) for a single pivotal Phase 3 clinical trial with the Company's lead product candidate APF530. The proposed trial will compare the safety and efficacy of APF530 with palonosetron (brand name ALOXI(R)) for the treatment of acute and delayed chemotherapy-induced nausea and vom... 
Printer Friendly Version
01/18/06A.P. Pharma Regains Compliance with NASDAQ National Market Listing Requirements; NASDAQ Believes Company in Compliance Based on Royalty Interest Sale
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 18, 2006--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, announces that based on the Company's recording of the gain on the sale of the royalty rights announced today, A.P. Pharma believes it has regained compliance for continued listing on the NASDAQ National Market by satisfying the NASDAQ's minimum stockholders' equity requirement of the NASDAQ National Marketplace Rule 4450(a)(3). NASDAQ will continue to monitor the... 
Printer Friendly Version
01/18/06A.P. Pharma Completes Financing for up to $30 Million; Sells Royalty Rights to Retin-A Micro and Carac; Transaction is Non-Dilutive to Shareholders
REDWOOD CITY, Calif., Jan 18, 2006 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA) today announced that it has sold rights to future royalties on sales of Retin-A Micro(R) and Carac(R) to an affiliate of the Paul Royalty Fund ("Paul Royalty") for up to $30 million. Proceeds of $25 million were received upon the closing of this transaction and will be used primarily to fund pivotal clinical development of APF530, A.P. Pharma's drug candidate for the prevention of acute and delayed che... 
Printer Friendly Version
11/16/05A.P. Pharma Reports Receipt of Notice from NASDAQ
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 16, 2005--A.P. Pharma, Inc. (NASDAQ NM: APPA), a specialty pharmaceutical company, today reported that on November 11, 2005, the Company was advised by the NASDAQ Listing Qualifications Department that NASDAQ is reviewing the Company's eligibility for continued listing on the NASDAQ National Market as the Company does not comply with the NASDAQ's minimum $10 million stockholders' equity requirement set forth in Marketplace Rule 4450(a)(3). T... 
Printer Friendly Version
11/04/05Dutton Associates Announces Investment Opinion: A.P. Pharma Raised to Strong Speculative Buy Rating in Update by Dutton Associates
EL DORADO HILLS, Calif., Nov 04, 2005 (BUSINESS WIRE) -- Dutton Associates updates its coverage of A.P. Pharma (Nasdaq:APPA) with an upgrade of its rating to Strong Speculative Buy. The 10-page report by Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. A.P. Pharma, Inc. (A.P. Pharma) is a small specialty pharmaceutical company seeking to develop and commercialize ... 
Printer Friendly Version
11/03/05A.P. Pharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 3, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference to be held November 7-9 at the Palace Hotel in New York City. Michael O'Connell, A.P. Pharma's president and chief executive officer, is scheduled to speak on Tuesday, November 8 at 4:35 PM Eastern Time (1:35 PM Pacific Time) and will discuss the Company's cl... 
Printer Friendly Version
11/02/05A.P. Pharma Reports Third Quarter Results; Preparations Underway for Pivotal Clinical Trials with APF530
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 2, 2005--A.P. Pharma, Inc. (NASDAQ NM: APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2005. Recent and Financial Highlights -- Phase 2 clinical trial using APF530 for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) was successfully completed, and all primary endpoints were achieved. -- ... 
Printer Friendly Version
10/26/05A.P. Pharma to Hold 2005 Third Quarter Financial Results Conference Call November 2
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2005 third quarter financial results prior to market open on Wednesday, November 2, 2005. Paul Goddard, chairman, and Company management will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday, November 2, 2005 to discuss the financial results, provide a business update... 
Printer Friendly Version
10/04/05A.P. Pharma to Hold APF530 Phase 2 Results Conference Call Today at 11:00 a.m. Eastern Time
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 4, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will hold an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, October 4, 2005. Management will host the call to elaborate on results from its APF530 Phase 2 clinical trial. In a press release issued on Thursday, September 29, 2005, the Company reported that all clinical endpoints in the Phase 2 study... 
Printer Friendly Version
09/29/05A.P. Pharma Reports All Clinical Endpoints Achieved in APF530 Phase 2 Trial; Conference Call to Begin at 11:00 A.M. Eastern Time Tuesday, October 4, 2005
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sept. 29, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported results from its APF530 Phase 2 clinical trial. All clinical endpoints were achieved and results support advancement of APF530 into pivotal clinical trials. The primary endpoints included an evaluation of safety, pharmacokinetics and tolerability. In addition, efficacy endpoints were evaluated relating to emetic events and the use of rescue medicat... 
Printer Friendly Version
08/08/05A.P. Pharma Reports Second Quarter Financial Results; Patient Enrollment for APF530 Phase 2 Trial Successfully Completed
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 8, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2005. Recent and Financial Highlights -- Patient enrollment in the open-label APF530 Phase 2 clinical trial has been successfully completed. APF530 is designed for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and contains the anti-nausea dr... 
Printer Friendly Version
07/29/05A.P. Pharma to Hold 2005 Second Quarter Financial Results Conference Call August 8
REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 29, 2005--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will release its 2005 second quarter financial results prior to market open on Monday, August 8, 2005. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, Aug... 
Printer Friendly Version
05/10/05A.P. Pharma Reports 2005 First Quarter Results; Cancer Patients Enrolled in Phase 2 Clinical Program for APF530
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 10, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2005. Recent and Financial Highlights -- APF530 Phase 2 clinical trial program underway for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. -- Primary endpoints are pharmacokinetics, safety and tolerability. ... 
Printer Friendly Version
05/03/05A.P. Pharma to Hold 2005 First Quarter Financial Results Conference Call May 10
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 3, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2005 first quarter financial results prior to market open on Tuesday, May 10, 2005. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, May 10,... 
Printer Friendly Version
04/28/05A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 28, 2005--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced the initiation of a Phase 2 clinical trial program in cancer patients with its lead product candidate, APF530, for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting. Using the Company's proprietary Biochronomer(TM) bioerodible drug delivery system with granisetron, APF530 is designed to provide therapeutic levels ... 
Printer Friendly Version
04/01/05Dutton & Associates Announces Investment Opinion: A.P. Pharma, Inc. Speculative Buy Rating in Update by Dutton Associates
EL DORADO HILLS, Calif., Apr 01, 2005 (BUSINESS WIRE) -- Dutton Associates updates coverage of A.P. Pharma, Inc. (Nasdaq:APPA), reiterating a Speculative Buy rating and our 12-month price of $3.00. The 12-page report by Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and other leading financial portals. A.P. Pharma, Inc. is a specialty pharmaceutical company seeking to develop and commercialize products utiliz... 
Printer Friendly Version
03/10/05A.P. Pharma Reports 2004 Fourth Quarter and Full Year Results; IND Submitted for APF530; Phase 2 Study Cleared to Begin in 2Q05
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 10, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for the three and 12 months ended December 31, 2004. Recent and Financial Highlights APF530 in development for the prevention of acute and delayed chemotherapy-induced nausea and vomiting progresses to Phase 2. Dose-ranging study confirms dose linearity and safety in healthy vo... 
Printer Friendly Version
03/03/05A.P. Pharma to Hold 2004 Fourth Quarter & Year-End Financial Results Conference Call March 10
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 3, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2004 fourth quarter and year-end financial results prior to market open on Thursday, March 10, 2005. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) ... 
Printer Friendly Version
11/15/04A.P. Pharma Reports Third Quarter Financial Results; APF530 Phase 1 Study Successfully Completed
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 15, 2004--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2004, reflecting increased royalty income and contract revenues as well as higher research and development expense due to the company's Phase 2 trial with APF112 (mepivacaine) and Phase 1 trial with APF530 (granisetron). Current Highlights Total revenues for the third quarter ... 
Printer Friendly Version
11/05/04A.P. Pharma to Hold 2004 Third Quarter Financial Results Conference Call November 15
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2004--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2004 third quarter financial results prior to market open on Monday, November 15, 2004. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, Nov... 
Printer Friendly Version
09/17/04A.P. Pharma to Hold Clinical and Business Update Conference Call September 21; Company to Discuss Development Plans for APF112 and APF530
REDWOOD CITY, Calif., Sep 17, 2004 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will hold an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, September 21, 2004. Paul Goddard, chairman, and Michael O'Connell, president and chief executive officer, will host the call to provide an update and elaborate on the company's action plan announced on August 12, 2004. This will include: ... 
Printer Friendly Version
08/12/04A.P. Pharma Reports Second Quarter Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 12, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2004, reflecting increased royalty income and contract revenues as well as higher research and development expense due to the company's Phase 2 trial with APF112 and Phase 1 trial with APF530. Second Quarter Financial Highlights -- Total revenues for the second quarter increased 15% to... 
Printer Friendly Version
08/12/04A.P. Pharma Reports Preliminary Clinical Data Results from Studies Using APF112 AND APF530; Conference Call to Begin Today at 12:00 Noon ET/9:00 a.m. PT
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 12, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported preliminary top-line results from the second part of the Phase 2 trial using APF112, and also reported initial Phase 1 data for APF530. APF112 is being tested for the treatment of pain following surgical inguinal hernia repair, and APF530 is being tested for the treatment of chemotherapy-induced nausea and vomiting. APF112 -- Safety and ... 
Printer Friendly Version
08/12/04A.P. Pharma to Hold Conference Call at 12 Noon Eastern Time Today to Discuss APF112 and APF530 Preliminary Trial Results, Second Quarter Financials
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 12, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will hold a conference call today beginning at 12:00 noon Eastern Time/9:00 a.m. Pacific Time today to discuss preliminary clinical data results from studies using APF112 and APF530, 2004 second quarter financial results and to answer questions. This conference call replaces the one previously scheduled for Monday, August 16, 2004. Paul Goddard, chairman, Michae... 
Printer Friendly Version
08/06/04A.P. Pharma to Hold 2004 Second Quarter Financial Results Conference Call August 16; Company to Report APF112 and APF530 Preliminary Trial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 6, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2004 second quarter financial results prior to market open on Monday, August 16, 2004. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, Augu... 
Printer Friendly Version
06/24/04A.P. Pharma Completes Common Stock Sale
REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 24, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today completed the sale of approximately 4.2 million shares of its common stock at a price of $3.00 per share to various institutional investors, for gross proceeds of approximately $12.5 million. The shares were offered and sold pursuant to an effective "shelf" registration statement, previously filed with the Securities and Exchange Commission. Olympus Securities L... 
Printer Friendly Version
05/05/04A.P. Pharma Files Shelf Registration Statement
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 5, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has filed a shelf registration statement with the Securities and Exchange Commission covering up to $15,000,000 of its common stock. The specific terms of any offering under the shelf registration will be established at the time of such offering. A registration statement relating to these securities has been filed with the Securities and Ex... 
Printer Friendly Version
04/28/04A.P. Pharma Reports First Quarter Results; Human Clinical Trials Underway with Two Product Candidates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 28, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2004. Current and Financial Highlights A Phase 2 human clinical trial is ongoing with APF112 for the treatment of post-surgical pain. Pre-clinical studies with APF530 for the treatment of chemotherapy-induced nausea and vomiting (CINV) are completed. ... 
Printer Friendly Version
04/21/04A.P. Pharma to Hold 2004 First Quarter Financial Results Conference Call April 28
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 21, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2004 first quarter financial results prior to market open on Wednesday, April 28, 2004. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Wednesday... 
Printer Friendly Version
04/16/04A.P. Pharma Initiates Phase I Clinical Trial with APF530, a Potential Treatment for Chemotherapy-Induced Nausea and Vomiting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 16, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced the initiation of a Phase I clinical study with APF530, its product candidate containing granisetron, for the treatment of chemotherapy-induced nausea and vomiting. The clinical study is designed to determine the safety and tolerability of APF530, and will include approximately 18 healthy volunteers at a single clinical site in the United Kingdo... 
Printer Friendly Version
03/12/04A.P. Pharma Reports 2003 Fourth Quarter and Full Year Results; Reports Results of Open-Label APF112 Phase 2 study
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 12, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three and 12 months ended December 31, 2003, and results from Part 1 of the APF112 Phase 2 clinical study. Recent and Financial Highlights APF112 Phase 2 study for the treatment of pain following inguinal hernia procedures is designed in two parts: Part 1 open-label study has been success... 
Printer Friendly Version
03/04/04A.P. Pharma to Hold 2003 Fourth Quarter and Full-Year Financial Results Conference Call March 12
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 4, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2003 fourth quarter and year-end financial results prior to market open on Friday, March 12, 2004. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on... 
Printer Friendly Version
02/24/04Study Indicates A.P. Pharma Polymer System Could Advance Clinical Utility of DNA Vaccines Against Cancer and Viral Infections; Data Published in Nature Materials
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 24, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that results of a study conducted at the Massachusetts Institute of Technology (MIT) indicate that a proprietary A.P. Pharma polymer delivery system could advance the clinical utility of DNA vaccines as well as other nucleic acid-based therapeutics against viral infections and cancers. Study results were reported in the paper, "Molecularly engineered p... 
Printer Friendly Version
01/26/04A.P. Pharma Provides APF112 Clinical Development Update; Phase II Data Expected by Mid-Year
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 26, 2004--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today provided an update on the clinical development of its lead product candidate, APF112. The multi-center Phase II study involving APF112 for the treatment of post-surgical pain, which commenced in the fourth quarter of 2003, is comprised of two parts. In November 2003, the Company indicated that they hoped to complete enrollment of this study in early 2004 a... 
Printer Friendly Version
11/07/03A.P. Pharma Reports Third Quarter Results; APF112 Phase II Clinical Trial Initiated; Royalty Income Increases 23% Over Q3 2002
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 7, 2003--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2003, reflecting increased royalty income and contract revenues. Current Highlights Phase II study using APF112 for the treatment of pain following inguinal hernia procedures has been initiated. IND for surgical/orthopedic indication follow-on product candid... 
Printer Friendly Version
10/30/03A.P. Pharma to Hold Third Quarter Conference Call November 7, 2003
REDWOOD CITY, Calif., Oct 30, 2003 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2003 third quarter financial results prior to market open on Friday, November 7, 2003. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Friday, Novem... 
Printer Friendly Version
09/17/03A.P. Pharma Receives Additional Patent for 5-FU Microsponge Formulation; Patent Covering Carac Formulation Extended to 2021
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sept. 17, 2003--A.P. Pharma, Inc. (Nasdaq:APPA) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) extending patent coverage to 2021 for the use of its Microsponge(R) delivery system in its formulation containing 5-fluorouracil. The Company receives royalties on this formulation from marketing partner Dermik Laboratories Inc., an Aventis company, on sales of Carac(TM) in the U.S. for ... 
Printer Friendly Version
08/26/03A.P. Pharma Ready to Initiate Phase II Studies With APF112; Company Plans to Initiate Phase II Clinical Trials in September
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 26, 2003--A.P. Pharma, Inc. (Nasdaq: APPA) today announced it intends to initiate a Phase II study for its post-surgical pain product, APF112, in the next month. In July, the Company submitted a comprehensive data package to the U.S. Food and Drug Administration (FDA) which included a proposed Phase II protocol. Following a review with FDA officials, the Company was given clearance to initiate the proposed clinical study. The Company intends to ... 
Printer Friendly Version
08/04/03A.P. Pharma Reports Second Quarter Results; APF112 Phase II Clinical Package Submitted for FDA Review; Royalty Income Increases 11% Over 2Q 2002
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 4, 2003--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2003, reflecting increased royalty income and contract revenues as well as higher research and development expenses as the Company prepares to initiate a Phase II clinical trial with APF112. Current Highlights Second quarter royalty income increased 11% to $1,031,000. Exten... 
Printer Friendly Version
07/24/03A.P. Pharma to Hold Second Quarter Conference Call August 4, 2003
REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 24, 2003--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2003 second quarter financial results prior to market open on Monday, August 4, 2003. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, August ... 
Printer Friendly Version
05/05/03A.P. Pharma Reports First Quarter Results; Royalty Income Increases by 14% Over Q1 2002
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 5, 2003--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2003. Results for the first quarter of 2003 reflect increased royalty income, as well as increased research and development expense as the Company prepares to enter Phase II clinical trials with APF112, its product candidate for the treatment of post-operative pain. First Quarter Highlights ... 
Printer Friendly Version
04/28/03A.P. Pharma to Hold First Quarter Conference Call May 5, 2003
REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 28, 2003--A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will release its 2003 first quarter financial results prior to market open on Monday, May 5, 2003. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, May 5, 20... 
Printer Friendly Version
02/27/03A.P. Pharma Reports Fourth Quarter and Year-End 2002 Results
REDWOOD CITY, Calif., Feb 27, 2003 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company focusing on the development of prescription pharmaceutical products using its proprietary Biochronomer(TM) drug delivery system, today reported financial results for the three and twelve months ended December 31, 2002. Recent Highlights: -- A plan has been implemented to enable APF112 to enter Phase II clinical testing for the treatment of pain in abdominal surgery i... 
Printer Friendly Version
02/21/03A.P. Pharma to Hold Fourth Quarter Conference Call February 27, 2003
REDWOOD CITY, Calif., Feb 21, 2003 (BUSINESS WIRE) -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2002 fourth quarter and year-end results prior to market open on Thursday, February 27, 2003. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursda... 
Printer Friendly Version
02/14/03A.P. Pharma Sells Non-Core Business for Cash and Royalties
REDWOOD CITY, Calif., Feb 14, 2003 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA) today reported it has sold its Analytical Standards division to GFS Chemicals, Inc., a private company based in Columbus, Ohio. The Analytical Standards business unit was no longer considered to be part of the strategic focus of the company. Terms of the sale included a cash payment of $2.1 million and a royalty on sales varying from 15% to 5% through 2007, with guaranteed minimum annual royalty payments.... 
Printer Friendly Version
12/11/02A.P. Pharma Names Robert L. Zerbe, M.D. To Board of Directors; New Member Brings To Board Additional Expertise in Regulatory Affairs and Clinical Development
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 11, 2002--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced the appointment of Robert L. Zerbe, M.D. to the Company's board of directors. Dr. Zerbe adds extensive experience in regulatory affairs and clinical development to the A.P. Pharma board. His board appointment brings the total number of directors to eight. Dr. Zerbe is the Chief Executive Officer and Founder of QuatRx Pharmaceutica... 
Printer Friendly Version
12/03/02A.P. Pharma Establishes Timetable to Re-Initiate Clinical Program for APF112; Company provides regulatory update on progress towards Phase II clinical studies
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 3, 2002--A.P. Pharma, Inc. (NASDAQ:APPA) today reported that Company executives have met with U.S. Food and Drug Administration (FDA) officials to review the Company's proposals to proceed with the clinical development of its lead proprietary product, APF112. The action plans agreed to at the meeting will be implemented immediately and, assuming that the preclinical testing proceeds as planned, the company expects to submit a new Pha... 
Printer Friendly Version
11/21/02A.P. Pharma Inc. CEO Michael O'Connell Talks to the Wall Street Transcript
NEW YORK--(BUSINESS WIRE)--Nov. 21, 2002--The Wall Street Transcript has published an in-depth interview with Michael O'Connell, President & CEO of A.P. Pharma, Inc. (Nasdaq:APPA), in which he talks at length about the Company's future. The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm. Michael gives an overview of the Company, "Our company went public in 1987 as Advanced Polymer Systems with a primary drug delivery f... 
Printer Friendly Version
11/07/02A.P. Pharma Reports Third Quarter Financial Results; Third Quarter Royalty Income Increases 30%
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 7, 2002--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2002. Highlights include: Royalty income increased 30% compared with the third quarter of last year, and increased 34% versus the first nine months of last year. Royalties from Johnson & Johnson sales of Retin-A Micro(R) increased 44% compared with the... 
Printer Friendly Version
10/31/02A.P. Pharma to Hold Third Quarter Conference Call November 7, 2002
REDWOOD CITY, Calif., Oct 31, 2002 (BUSINESS WIRE) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2002 third quarter results prior to market open on Thursday, November 7, 2002. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, November 7, 2... 
Printer Friendly Version
08/16/02A.P. Pharma to Conduct Additional Preclinical Testing With APF112; Company Withdraws Proposed Phase II Protocol
REDWOOD CITY, Calif., Aug 16, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (NASDAQ:APPA) announced today that it has withdrawn the proposed protocol for a Phase II clinical study for its product APF112 for the short-term treatment of post-surgical pain. This action was taken in response to questions raised by the U.S. Food and Drug Administration (FDA) concerning observations of irritation in preclinical studies in both active and control animal groups. This irritation, which was mild to mode... 
Printer Friendly Version
08/05/02A.P. Pharma Reports Second Quarter Financial Results; Royalty Income Continues to Increase; Clinical Programs Advance with Additional Corporate Collaborators
REDWOOD CITY, Calif., Aug 5, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2002. Highlights include: Royalty income increased 34% compared with the second quarter of last year and increased 36% versus the first half of last year; The Company's third U.S. FDA-approved product, a low-dose version of Retin-A Micro(R), was launched in July by... 
Printer Friendly Version
07/29/02A.P. Pharma to Hold Second Quarter Conference Call August 5, 2002
REDWOOD CITY, Calif., Jul 29, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, will release its 2002 second quarter results prior to market open on Monday, August 5, 2002. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, August 5, 2002 to... 
Printer Friendly Version
05/15/02Second Formulation of RETIN-A MICRO Approved for U.S. Market; Launch Anticipated in June 2002; Potential to Significantly Increase A.P. Pharma's Royalties
REDWOOD CITY, Calif.--(BW HealthWire)--May 15, 2002--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, said today that the U.S. Food and Drug Administration (FDA) has granted Ortho Neutrogena marketing approval for RETIN-A MICRO(R) 0.04%, (tretinoin gel) microsphere, 0.04%, a new, lower-dose formulation of RETIN-A MICRO, a leading topical acne treatment. As part of an existing licensing agreement with A.P. Pharma, Ortho Neutrogena, a Johnson and Jo... 
Printer Friendly Version
05/07/02A.P. Pharma Reports First Quarter Results; Clinical Program for APF112 Initiated in 2002; Royalty Income Up 39% Over First Quarter 2001
REDWOOD CITY, Calif., May 7, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2002, reflecting increased royalty income as well as increased research and development expense as the company entered Phase I clinical trials. Current Highlights: Clinical development of post-surgical pain product, APF112, initiated in first quarter 2002; efficacy studies ... 
Printer Friendly Version
05/01/02A.P. Pharma to Hold First Quarter Conference Call May 7, 2002
REDWOOD CITY, Calif., May 1, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (NASDAQ NM:APPA), a specialty pharmaceutical company, will release its 2002 first quarter results prior to market open on Tuesday, May 7, 2002. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, May 7, 2002 to dis... 
Printer Friendly Version
03/05/02A.P. Pharma Reports Fourth Quarter and Year-End 2001 Results; Substantial Progress for the Biochronomer Drug Delivery System in 2001
REDWOOD CITY, Calif., Mar 5, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today reported financial results for the three months and full-year ended December 31, 2001, reflecting increased royalty income as well as increased research and development expense relating to the filing of its first Investigational New Drug application (IND). "The Company made substantial progress during 2001," commented Dr. Paul Goddard, A.P Pharma's Chairman. "... 
Printer Friendly Version
02/26/02A.P. Pharma To Hold Fourth Quarter Conference Call March 5, 2002
REDWOOD CITY, Calif., Feb 26, 2002 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2001 fourth quarter and year-end financial results prior to market open on Tuesday, March 5, 2002. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tu... 
Printer Friendly Version
01/29/02A.P. Pharma Reports Initiation of Clinical Program for APF112; First Clinical Study Fully Enrolled
REDWOOD CITY, Calif.--(BW HealthWire)--Jan. 29, 2002--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported the successful completion of its initial Phase I clinical study with APF 112, its lead product candidate for the treatment of post-surgical pain. The initial clinical study was designed to measure the safety and tolerability of APF 112, and results indicated that APF 112 caused no adverse events in the 16 subjects. A.P. Pharma is curren... 
Printer Friendly Version
12/20/01A.P. Pharma Files First Investigational New Drug Application for APF112 Formulation Using Biochronomer System
Lead Product for Post-Surgical Pain Cleared to Commence Phase I Clinical Trials REDWOOD CITY, Calif.--(BW HealthWire)--Dec. 20, 2001-- A.P. Pharma Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials of APF 112, the company's lead product candidate for the treatment of post-surgical pain. The company will begin its ... 
Printer Friendly Version
11/06/01A.P. Pharma Reports Third Quarter 2001 Results; Carac Achieves 26% Topical Market Share in Second Quarter after Launch
REDWOOD CITY, Calif., Nov 6, 2001 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended September 30, 2001. Highlights of the Third Quarter Include: All studies required for Investigational New Drug (IND) filing for the treatment of post-surgical pain using the Biochronomer(TM) bioerodible system, now completed Multiple collaborative product-specific feasib... 
Printer Friendly Version
10/31/01A.P. Pharma to Hold Third Quarter 2001 Conference Call Nov. 6, 2001
REDWOOD CITY, Calif., Oct 31, 2001 (BUSINESS WIRE) -- A.P. Pharma Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release 2001 third quarter financial results prior to market open on Tuesday, Nov. 6, 2001. Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, Nov. 6, 2001 ... 
Printer Friendly Version
09/26/01Second New Drug Application Filed for Retin-A Micro; Potential to Significantly Increase A.P. Pharma's Royalties
REDWOOD CITY, Calif., Sep 26, 2001 (BW HealthWire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that a New Drug Application (NDA) has been filed with the U.S. Food and Drug Administration (FDA) for a second formulation of Retin-A Micro(R), a leading topical acne treatment. Retin-A Micro was the first ethical pharmaceutical product to contain the patented Microsponge(R) delivery systems and is one of the leading products in the $500 million-pe... 
Printer Friendly Version
08/07/01A.P. Pharma Reports Second Quarter 2001 Results; Royalty Income Increases, Proprietary Product-Development Programs Underway
REDWOOD CITY, Calif.--(BW HealthWire)--Aug. 7, 2001--A.P. Pharma Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today reported financial results for the three months ended June 30, 2001. Second Quarter Highlights Include: Toxicology studies indicate safety of first-generation Biochronomer(TM) -- Phase I clinical trials planned for first half of 2002 -- Royalty stream increases -- Retin-A Micro(R) continues as a leading acne treatment, Carac(TM) gai... 
Printer Friendly Version
07/23/01Retin-A Micro Receives Marketing Clearance in Canada; Johnson & Johnson Canada to Market Prescription Acne Treatment Containing Microsponge Systems in Canada
REDWOOD CITY, Calif., Jul 23, 2001 (BW Health Wire) -- A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that Canadian drug regulatory authorities have granted marketing clearance for Retin-A Micro(R) (tretinoin gel) microsphere, 0.1% for the treatment of acne. This topical medication was launched in the U.S. in 1997, becoming the first ethical pharmaceutical to contain the patented Microsponge(R) delivery systems. Retin-A Micro is one of the leading ... 
Printer Friendly Version
06/26/01A.P. Pharma Successfully Completes Pre-Clinical Safety Evaluations Of Biochronomer™ System
Plans to Commence Human Clinical Trials in First Half 2002 REDWOOD CITY, Calif. (June 26, 2001) – A.P. Pharma, Inc. (NASDAQ NM: APPA), a company focused on the development of ethical pharmaceuticals utilizing proprietary polymer-based drug delivery systems, today announced that it has successfully completed a series of pre-clinical safety studies on the company's patented polymer-based system, trade named Biochronomer™. The results of these studies indicate that the first generation ... 
Printer Friendly Version
06/01/01A.P. Pharma To Present At Wall Street Analyst Forum, June 7
40TH Institutional Investor Conference REDWOOD CITY, Calif. (June 1, 2001) – A.P. Pharma, Inc. (NASDAQ NM: APPA), a specialty pharmaceutical company, today announced that it will be presenting to analysts and portfolio managers at the Wall Street Analyst Forum's Institutional Investor Conference, being held at the Roosevelt Hotel, New York. Mike O'Connell, A.P. Pharma's president and chief executive officer, will be presenting at 1:50 p.m. Eastern Time on Thursday, June 7. A.P... 
Printer Friendly Version
05/30/01A.P. Pharma Appoints Vice President Of Business Development
Newly Created Position is Instrumental in Company's Business Strategy REDWOOD CITY, Calif. (May 30, 2001) – A.P. Pharma, Inc. (Nasdaq NM: APPA), a specialty pharmaceutical company, today announced the appointment of Jayne M. Lange to the newly created position of Vice President, Business Development. Ms. Lange primarily will be responsible for developing corporate partnerships and collaborations for the Company's families of bioerodible delivery systems for injectable and implantable ... 
Printer Friendly Version
05/14/01Advanced Polymer Systems Changes Name To A.P. Pharma
Company common stock to trade on Nasdaq under the symbol APPA New name reflects new Company strategy REDWOOD CITY, Calif. (May 14, 2001) – Advanced Polymer Systems, Inc. (Nasdaq NM: APOS), a specialty pharmaceutical company, today reported that shareholders have approved a change in the Company's name to A.P. Pharma, Inc. The resolution to change the corporate name was passed at the Annual Shareholders' Meeting held on May 9, 2001. Effective with the opening of trading on May 14, 200... 
Printer Friendly Version
05/03/01Advanced Polymer Systems Reports First Quarter 2001 Results
Royalty Income from Dermik's Carac Commences REDWOOD CITY, Calif. (May 3, 2001) – Advanced Polymer Systems (Nasdaq NM: APOS), a specialty pharmaceutical company focused on the development of ethical pharmaceuticals utilizing its proprietary drug delivery systems, today reported financial results for the three months ended March 31, 2001 and highlighted progress in the first quarter. Highlights of the 2001 first quarter included: » A second prescription formulation (Carac™) utilizin... 
Printer Friendly Version
04/12/01Advanced Polymer Systems To Begin Receiving Royalties From Sales Of Dermik’s Carac™ For Treatment Of Actinic Keratoses
Second Prescription Formulation to Utilize Microsponge ® System Developed by Advanced Polymer Systems REDWOOD CITY, Calif. (April 12, 2001) – Advanced Polymer Systems (Nasdaq NM: APOS), today announced the launch by its development and marketing partner, Dermik Laboratories, Inc., a subsidiary of Aventis Pharma AG, of the first FDA-approved once-a-day topical prescription product under the trade name Carac™ for the treatment of actinic keratoses (AK). Advanced Polymer Systems, which is... 
Printer Friendly Version
03/13/01Advanced Polymer Systems Reports Fourth Quarter And Full-Year 2000 Results
REDWOOD CITY, Calif. (March 13, 2001) – Advanced Polymer Systems (NasdaqNM: APOS), an innovator in polymer-based drug delivery systems, today reported its fourth quarter and full-year 2000 results. Total revenues from continuing operations for the year ended December 31, 2000 were $3,366,000, compared with $4,697,000 for 1999, a decrease of $1,331,000, due mainly to the absence of the one-time sale of a proprietary product line in the prior year. Net loss from continuing operations for... 
Printer Friendly Version
11/01/00Advanced Polymer Systems Appoints Experienced Pharmaceutical Industry Executive As Chairman
Paul Goddard Joins Board as Chairman as of November 1, 2000 REDWOOD CITY, Calif., November 1, 2000 – The Board of Directors of Advanced Polymer Systems (Nasdaq: APPA) today announced that it has appointed Paul Goddard, PhD. as Chairman of its Board of Directors effective November 1, 2000. Dr. Goddard succeeds John J. Meakem, Jr., who is stepping down as the Company's Chairman. Mr. Meakem's retirement and the search for a successor had been previously announced. Dr. Goddard, who remai... 
Printer Friendly Version
10/30/00FDA Grants Marketing Clearance For New Formulation
Microsponge ® System Used in New Drug Product for Actinic Keratoses REDWOOD CITY, Calif., October 30, 2000 – Advanced Polymer Systems, Inc. (Nasdaq: APOS) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing clearance for a new Microsponge ® formulation of 5-fluorouracil (5-FU), a treatment for actinic keratoses. This unique formulation of 5-fluorouracil, which utilizes Advanced Polymer's patented Microsponge system, has demonstrated efficacy in ... 
Printer Friendly Version
08/02/00Advanced Polymer Systems Announces Key Management Changes
Gordon Sangster Appointed CFO; John Barr Appointed Vice President of Research and Development REDWOOD CITY, CA, August 2, 2000 – Advanced Polymer Systems (NASDAQ: APOS), a leader in polymer-based delivery systems and related technologies, today announced that it has appointed Gordon Sangster to chief financial officer and John Barr to post of vice president of research and development. Sangster and Barr will report directly to Michael P.J. O'Connell, who, as previously announced, assum... 
Printer Friendly Version
07/26/00Advanced Polymer Systems Completes Sale Of Cosmeceutical Product Lines And Technology Rights For Certain Topical Pharmaceuticals To R.P. Scherer
Deal Calls for $25 Million Up-front Payment and Potential of Additional $26.5 Million in Performance Payments Meakem to Retire, O'Connell to Assume President/CEO Posts REDWOOD CITY, CA, July 26, 2000 – Advanced Polymer Systems (NASDAQ: APOS) today announced the successful completion of the sale of its cosmeceutical product lines and technology rights for certain topical pharmaceuticals to R.P. Scherer Corporation, a subsidiary of Cardinal Health, Inc. In the transaction, Advanced ... 
Printer Friendly Version